Companies DocGo Inc.
DocGo (DCGO): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me DocGo Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $11,351,018FY2023
- $7,562,418FY2024
- $3,571,951FY2025
CEO total pay was $3,571,951 in fiscal 2025, down from $7,562,418 in fiscal 2024.
FY2025: salary $785,000 · bonus $0 · stock awards $1,926,346 · option awards $0
Executives and directors
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Lee Bienstock | $785,000 | $0 | $1,926,346 | $0 | $831,315 | $0 | $29,290 | $3,571,951 |
| Chief Executive Officer and Director | ||||||||
| Norman Rosenberg | 492,000 | 0 | 742,870 | 0 | 432,453 | 0 | 29,290 | 1,696,614 |
| Chief Financial Officer and Treasurer | ||||||||
| Ely Tendler | 0 | 0 | 92,000 | 0 | 0 | 0 | 1,225,422 | 1,317,422 |
| General Counsel, Secretary and Director | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Lee Bienstock | $3,571,951 | $7,562,418 | $11,351,018 | ↓ −3,990,467 |
| Norman Rosenberg | 1,696,614 | 4,792,931 | 4,165,038 | ↓ −3,096,317 |
| Ely Tendler | 1,317,422 | 1,357,845 | 1,596,370 | ↓ −40,423 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Our executive compensation program is designed to align executive compensation with the Company’s business objectives and the creation of stockholder value, while enabling the Company to attract, motivate and retain individuals who contribute to its long-term success. The program links a significant portion of cash compensation to performance objectives and provides a significant portion of compensation as long-term incentive compensation in the form of equity awards.
| CEO STI target (% of salary) | 100% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Compensia |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | false |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Norman Rosenberg | PSU | — | — | — | — | — | $742,870 |
| Lee Bienstock | PSU | — | — | — | — | — | 1,926,346 |
| Ely Tendler | PSU | — | — | — | — | — | 92,000 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Norman Rosenberg | $0 | $742,870 | $0 | 100.0% |
| Lee Bienstock | 0 | 1,926,346 | 0 | 100.0% |
| Ely Tendler | 0 | 92,000 | 0 | 100.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Ely Tendler | RSU | 17,900 | — | $15,752 |
| Lee Bienstock | Option | 22,370 | 6.93 | — |
| Lee Bienstock | RSU | 36,713 | — | 32,307 |
| Lee Bienstock | RSU | 47,147 | — | 41,489 |
| Ely Tendler | RSU | 48,449 | — | 42,635 |
| Norman Rosenberg | Option | 53,315 | 8.61 | — |
| Lee Bienstock | RSU | 60,975 | — | 53,658 |
| Lee Bienstock | Option | 75,282 | 5.16 | — |
| Lee Bienstock | Option | 80,032 | 7.15 | — |
| Norman Rosenberg | PSU | 85,271 | — | 75,038 |
| Norman Rosenberg | Option | 96,647 | 6.93 | — |
| Ely Tendler | RSU | 100,000 | — | 88,000 |
| Lee Bienstock | Option | 105,423 | 8.61 | — |
| Norman Rosenberg | RSU | 106,589 | — | 93,798 |
| Norman Rosenberg | PSU | 115,354 | — | 101,512 |
| Lee Bienstock | PSU | 178,998 | — | 157,518 |
| Lee Bienstock | PSU | 232,558 | — | 204,651 |
| Norman Rosenberg | RSU | 259,546 | — | 228,400 |
| Lee Bienstock | RSU | 290,697 | — | 255,813 |
| Lee Bienstock | RSU | 402,745 | — | 354,416 |
| Norman Rosenberg | RSU | 429,405 | — | 377,876 |
| Norman Rosenberg | PSU | 429,405 | — | 377,876 |
| Lee Bienstock | RSU | 1,113,495 | — | 979,876 |
| Lee Bienstock | PSU | 1,113,495 | — | 979,876 |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Stephen K. Klasko, MDIndependent · Board Chair · Audit and Compliance Committee · Nominating and Corporate Governance Committee · Departed during FY | $249,000 | $151,000 | — | — | — | $400,000 |
| Ira SmedraIndependent · Compensation Committee (Chair) · Nominating and Corporate Governance Committee (Chair) | 96,250 | 138,000 | — | — | — | 234,250 |
| Michael BurdiekIndependent · Audit and Compliance Committee (Chair) · Compensation Committee | 87,500 | 138,000 | — | — | — | 225,500 |
| Vina LeiteIndependent · Compensation Committee · Nominating and Corporate Governance Committee | 70,000 | 138,000 | — | — | — | 208,000 |
| James M. TraversIndependent · Audit and Compliance Committee · Nominating and Corporate Governance Committee | 55,000 | 138,000 | — | — | — | 193,000 |
| Lee BienstockEmployee director | — | — | — | — | — | 0 |
| Ely D. TendlerEmployee director | — | — | — | — | — | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $55,000 |
|---|---|
| Annual equity retainer | $150,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 22,500 / 20,000 / 10,000 |
| Stock ownership guideline | $5 |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $557,750 |
| Equity awards (grant-date value) | $703,000 |
| All other compensation | $0 |
| Total cost of the board | $1,260,750 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names DocGo as a peer
Companies that benchmark against DCGO
3 companies name DCGO as a compensation peer
The list of companies that name DCGO as a peer is temporarily unavailable — recheck shortly.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Peer reciprocity
Of the companies DocGo Inc. names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer’s own current proxy has been read — each mark is cited in the register to that peer’s filing. A dash means the peer’s current proxy was read and names no reciprocal group including DocGo Inc..
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | GeneDx Holdings Corp. | 2025 | Katherine Stueland | $715,869 | $11,738,600 | $0 | $1,075,500 | $13,547,219 |
| 2 | Definitive Healthcare Corp. | 2025 | Kevin Coop | 500,000 | 7,696,741 | 0 | 384,875 | 8,604,138 |
| 3 | Phreesia, Inc. | 2026 | Chaim Indig | 515,000 | 7,562,706 | 0 | 0 | 8,077,706 |
| 4 | LifeStance Health Group, Inc. | 2025 | David Bourdon | 657,692 | 5,257,623 | 0 | 716,065 | 6,645,380 |
| 5 | InnovAge Holding Corp. | 2026 | Patrick Blair | 788,577 | 599,997 | 3,583,689 | 793,000 | 6,168,963 |
| 6 | Accuray Inc. | 2026 | Steve La Neve | 525,000 | 4,263,749 | 0 | 0 | 5,114,466 |
| 7 | Aveanna Healthcare Holdings, Inc. | 2025 | Jeffrey Shaner | 750,000 | 2,603,993 | 0 | 1,500,000 | 4,864,165 |
| 8 | OraSure Technologies, Inc. | 2025 | Carrie Eglinton Manner | 721,000 | 3,394,188 | 0 | 173,040 | 4,292,228 |
| 9 | American Well Corporation | 2025 | Ido Schoenberg | 701,755 | 1,294,331 | 0 | 2,010,100 | 4,162,171 |
| 10 | Health Catalyst, Inc. | 2025 | Daniel Burton | 525,000 | 3,444,040 | 0 | 0 | 3,991,159 |
| 11 | Accolade, Inc. | 2024 | Rajeev Singh | 500,000 | 3,320,097 | 0 | 0 | 3,823,597 |
| 12 | The Pennant Group, Inc. | 2025 | Brent Guerisoli | 444,711 | 662,117 | 885,588 | 1,737,874 | 3,739,476 |
| 13 | DocGo Inc. | 2025 | Lee Bienstock | 785,000 | 1,926,346 | 0 | 831,315 | 3,571,951 |
| 14 | Enhabit, Inc. | 2024 | Barbara Jacobsmeyer | 850,000 | 2,065,211 | 0 | 223,125 | 3,140,924 |
| 15 | Viemed Healthcare, Inc. | 2025 | Casey Hoyt | 549,383 | 1,515,810 | 0 | 511,301 | 2,626,271 |
| 16 | ModivCare Inc. | 2024 | L. Heath Sampson | 792,885 | 1,685,011 | 0 | 0 | 2,520,122 |
| — | Sharecare, Inc. | — | — | — | — | — | — | not in coverage universe |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| DocGo Inc. | 105.9% | RSU 50 · PSU 50 | Yes — TSR relative to the TSR of the constituents of the Nasdaq Health Care Index | Compensia |
| Accolade, Inc. | not disclosed | PSU 50 · RSU 50 | No | FW Cook |
| Accuray Inc. | 0% | PSU 50 · RSU 50 | No | Exequity LLP |
| American Well Corporation | not disclosed | PSU 45 · Cash LTI 45 · RSU 10 | No | Aon |
| Aveanna Healthcare Holdings, Inc. | 200% | PSU 50 · RSU 50 | No | Aon Human Capital Solutions (division of Aon plc) |
| Definitive Healthcare Corp. | not disclosed | not disclosed | Yes — relative TSR | not disclosed |
| Enhabit, Inc. | not disclosed | PSU 60 · RSU 40 | not disclosed | Pay Governance |
| GeneDx Holdings Corp. | 150% | PSU 50 · RSU 50 | No | Pearl Meyer |
| Health Catalyst, Inc. | 39% | RSU 50 · PRSU 50 | Yes — TSR Achievement | Aon |
| InnovAge Holding Corp. | not disclosed | not disclosed | not disclosed | not disclosed |
| LifeStance Health Group, Inc. | not disclosed | not disclosed | not disclosed | Pay Governance |
| ModivCare Inc. | not disclosed | PRSU 60 · RSU 40 | not disclosed | Meridian Compensation Partners, LLC |
| OraSure Technologies, Inc. | 24.0% | RSU 50 · PSU 50 | Yes — Relative TSR performance vs peer group | Pay Governance |
| Phreesia, Inc. | 140.3% | PSU 50 · RSU 50 | Yes — Relative TSR | FW Cook, Inc. |
| Sharecare, Inc. | 47% | RSU 75 · PSU 25 | No | not disclosed |
| The Pennant Group, Inc. | not disclosed | not disclosed | not disclosed | The Company engages periodically with a Compensation Adviser to review and advise the Compensation Committee on the Company's executive compensation. The Compensation Committee did not retain a Compensation Adviser relating to executive compensation in 2025, but did reference compensation studies performed for the Company previously. |
| Viemed Healthcare, Inc. | not disclosed | not disclosed | not disclosed | Arthur J. Gallagher & Co. |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-16 | 39,768,972 | 10,213,238 | 183,325 | 79.28% | Passed |
| 2025 | 2025-06-17 | 47,948,090 | 18,150,345 | 855,499 | 71.61% | Passed |
| 2024 | 2024-06-18 | 38,170,534 | 14,578,371 | 70,604 | 72.27% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-16 | 79.28%a |
| 2025 | 2025-06-17 | 71.61%b |
| 2024 | 2024-06-18 | 72.27%c |
a. Approved under the standard stated in the filing — “Abstentions will have the same effect as a vote "AGAINST", and broker non -votes , if any, will have no effect on Proposal 2.”.
b. Approved under the standard stated in the filing — “Abstentions will have the same effect as a vote "AGAINST", and broker non -votes , if any, will have no effect on Proposal 2.”.
c. Approved under the standard stated in the filing — “Abstentions will have the same effect as a vote "AGAINST", and broker non -votes , if any, will have no effect on Proposal 2.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Lee Bienstock | Director | 2026-05-12 | D | 15,644 | $1 | $9,230 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (51 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Lee Bienstock. DEF 14A, filed 2026-04-22. Section “2025 Summary Compensation Table” · page 16. As printed: 3,571,951. View filing ↗
- Section 01, Norman Rosenberg. DEF 14A, filed 2026-04-22. Section “2025 Summary Compensation Table” · page 16. As printed: 1,696,614. View filing ↗
- Section 01, Ely Tendler. DEF 14A, filed 2026-04-22. Section “2025 Summary Compensation Table” · page 16. As printed: 1,317,422. View filing ↗
- Section 03, Norman Rosenberg PSU. DEF 14A, filed 2026-04-22. Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 03, Lee Bienstock PSU. DEF 14A, filed 2026-04-22. Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 03, Ely Tendler PSU. DEF 14A, filed 2026-04-22. Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. 10-K, filed 2026-03-16. Section “CEO Pay Ratio”. As printed: —. View filing ↗
- Section 08, Stephen K. Klasko, MD. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 400,000. View filing ↗
- Section 08, Ira Smedra. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 234,250. View filing ↗
- Section 08, Michael Burdiek. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 225,500. View filing ↗
- Section 08, Vina Leite. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 208,000. View filing ↗
- Section 08, James M. Travers. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 193,000. View filing ↗
- Section 08, Lee Bienstock. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Ely D. Tendler. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Lee Bienstock 2026-05-12. Form 4, filed 2026-05-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-18. Item 5.07 · say-on-pay result. As reported: 79.28% (votes for as printed: 39,768,972). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-18. Item 5.07 · say-on-pay result. As reported: 71.61% (votes for as printed: 47,948,090). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-18. Item 5.07 · say-on-pay result. As reported: 72.27% (votes for as printed: 38,170,534). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 557,750 + equity 703,000 + all other 0 = 1,260,750, summed across the director compensation table rows.
- GeneDx Holdings Corp., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in GeneDx Holdings Corp.'s own proxy. As printed: 13,547,219. View filing ↗
- Definitive Healthcare Corp., Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Definitive Healthcare Corp.'s own proxy. As printed: 8,604,138. View filing ↗
- Phreesia, Inc., Section 10b CEO total. DEF 14A, filed 2026-05-14. CEO total compensation as printed in Phreesia, Inc.'s own proxy. As printed: 8,077,706. View filing ↗
- LifeStance Health Group, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in LifeStance Health Group, Inc.'s own proxy. As printed: 6,645,380. View filing ↗
- InnovAge Holding Corp., Section 10b CEO total. DEF 14A, filed 2026-10-22. CEO total compensation as printed in InnovAge Holding Corp.'s own proxy. As printed: 6,168,963. View filing ↗
- Accuray Inc., Section 10b CEO total. DEF 14A, filed 2026-10-16. CEO total compensation as printed in Accuray Inc.'s own proxy. As printed: 5,114,466. View filing ↗
- Aveanna Healthcare Holdings, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-17. CEO total compensation as printed in Aveanna Healthcare Holdings, Inc.'s own proxy. As printed: 4,864,165. View filing ↗
- OraSure Technologies, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in OraSure Technologies, Inc.'s own proxy. As printed: 4,292,228. View filing ↗
- American Well Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in American Well Corporation's own proxy. As printed: 4,162,171. View filing ↗
- Health Catalyst, Inc., Section 10b CEO total. DEF 14A, filed 2026-06-03. CEO total compensation as printed in Health Catalyst, Inc.'s own proxy. As printed: 3,991,159. View filing ↗
- Accolade, Inc., Section 10b CEO total. DEF 14A, filed 2024-06-21. CEO total compensation as printed in Accolade, Inc.'s own proxy. As printed: 3,823,597. View filing ↗
- The Pennant Group, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-31. CEO total compensation as printed in The Pennant Group, Inc.'s own proxy. As printed: 3,739,476. View filing ↗
- DocGo Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in DocGo Inc.'s own proxy. As printed: 3,571,951. View filing ↗
- Enhabit, Inc., Section 10b CEO total. DEF 14A, filed 2025-05-16. CEO total compensation as printed in Enhabit, Inc.'s own proxy. As printed: 3,140,924. View filing ↗
- Viemed Healthcare, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Viemed Healthcare, Inc.'s own proxy. As printed: 2,626,271. View filing ↗
- ModivCare Inc., Section 10b CEO total. DEF 14A, filed 2025-04-30. CEO total compensation as printed in ModivCare Inc.'s own proxy. As printed: 2,520,122. View filing ↗
- Section 10a, American Well Corporation reciprocity. DEF 14A. American Well Corporation's most recent proxy was read; its disclosed peer group does not include DocGo Inc.. View filing ↗
- Section 10a, GeneDx Holdings Corp. reciprocity. DEF 14A. GeneDx Holdings Corp.'s most recent proxy was read; its disclosed peer group does not include DocGo Inc.. View filing ↗
- Section 10a, Health Catalyst, Inc. reciprocity. DEF 14A. Health Catalyst, Inc. names DocGo Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, LifeStance Health Group, Inc. reciprocity. DEF 14A. LifeStance Health Group, Inc.'s most recent proxy was read; its disclosed peer group does not include DocGo Inc.. View filing ↗
- Section 10a, OraSure Technologies, Inc. reciprocity. DEF 14A. OraSure Technologies, Inc.'s most recent proxy was read; its disclosed peer group does not include DocGo Inc.. View filing ↗
- Section 10a, Phreesia, Inc. reciprocity. DEF 14A. Phreesia, Inc.'s most recent proxy was read; its disclosed peer group does not include DocGo Inc.. View filing ↗
- Section 10a, Definitive Healthcare Corp. reciprocity. DEF 14A. Definitive Healthcare Corp.'s most recent proxy was read; its disclosed peer group does not include DocGo Inc.. View filing ↗
- Section 10a, Accuray Inc. reciprocity. DEF 14A. Accuray Inc.'s most recent proxy was read; its disclosed peer group does not include DocGo Inc.. View filing ↗
- Section 10a, Aveanna Healthcare Holdings, Inc. reciprocity. DEF 14A. Aveanna Healthcare Holdings, Inc.'s most recent proxy was read; its disclosed peer group does not include DocGo Inc.. View filing ↗
- Section 10a, Accolade, Inc. reciprocity. DEF 14A. Accolade, Inc.'s most recent proxy was read; its disclosed peer group does not include DocGo Inc.. View filing ↗
- Section 10a, Enhabit, Inc. reciprocity. DEF 14A. Enhabit, Inc. names DocGo Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, ModivCare Inc. reciprocity. DEF 14A. ModivCare Inc.'s most recent proxy was read; its disclosed peer group does not include DocGo Inc.. View filing ↗
- Section 10a, Sharecare, Inc. reciprocity. DEF 14A. Sharecare, Inc.'s most recent proxy was read; its disclosed peer group does not include DocGo Inc.. View filing ↗
- Section 10a, The Pennant Group, Inc. reciprocity. DEF 14A. The Pennant Group, Inc.'s most recent proxy was read; its disclosed peer group does not include DocGo Inc.. View filing ↗